Publication

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Banerjee, S. N.
; 
Ring, S.
; 
Van Nieuwenhuysen, E.
; 
Fabbro, M.
; 
Aghajanian, C.
; 
Oaknin, A.
; 
Colombo, N.
; 
Santin, A.
; 
Clamp, Andrew R
; 
Moore, K. N.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Banerjee, S. N.
Ring, S.
Van Nieuwenhuysen, E.
Fabbro, M.
Aghajanian, C.
Oaknin, A.
Colombo, N.
Santin, A.
Clamp, Andrew R
Moore, K. N.
Rose, P. G.
O'Malley, D. M.
Chon, H. S.
Salinas, E. A.
Prendergast, E. N.
Lustgarten, S.
Rodrigues, M.
Gennigens, C.
Monk, B. J.
Grisham, R. N.
Affiliation
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI), London
Description
Date
2023
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Ring S, Van Nieuwenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003028.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626644
Embedded videos